Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on April 11, 2018. The filing discloses the execution of amended and restated employment agreements with four key executive officers: Yuval Cohen (CEO), Mark Tepper (President and CSO), Barbara White (CMO), and Sean Moran (CFO). The Company is designated as an emerging growth company.
Key Financial Metrics and Compensation Terms
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It details the following compensation terms effective April 11, 2018:
- Yuval Cohen (CEO): Annual base salary of $540,000; target annual bonus of 55% of base salary.
- Mark Tepper (President/CSO): Annual base salary of $390,000; target annual bonus of 45% of base salary.
- Barbara White (CMO): Annual base salary of $424,000; target annual bonus of 40% of base salary.
- Sean Moran (CFO): Annual base salary of $375,000; target annual bonus of 40% of base salary.
All executives are eligible for equity awards under existing or future plans. All agreements include non-compete and non-solicitation provisions for 12 months post-employment.
Material Changes and Severance Provisions
The primary material change is the renewal of executive contracts for a two-year term expiring April 11, 2020. The agreements establish specific severance packages:
- Standard Termination (Without Cause/Good Reason): 12 months of base salary plus 12 months of COBRA coverage and a pro-rated bonus.
- Change in Control Termination:
- CEO: 24 months of base salary, 24 months of COBRA, accelerated equity vesting, and 2x target bonus.
- Other Executives: 18 months of base salary, 18 months of COBRA, accelerated equity vesting, and 1x target bonus.
Severance payments are subject to reduction if necessary to avoid excise taxes under Internal Revenue Code Section 4999.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the potential financial impact of a Change in Control, which triggers enhanced severance and equity acceleration. The agreements also include standard confidentiality and invention assignment provisions.
Investor Verification Checklist
- Verify the total annual fixed compensation cost increase resulting from these new agreements compared to prior terms.
- Review the attached Exhibits 10.1 through 10.4 for specific performance metrics tied to the annual bonuses.
- Assess the potential liability exposure for the Company in the event of a Change in Control, specifically the 24-month severance for the CEO.
- Confirm the Company's current cash position to ensure it can sustain these executive compensation levels given its pre-revenue status.